Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study

We report on the safety and immunogenicity of idiotypic DNA vaccination in a phase I, non-randomised, open-label study in patients with multiple myeloma. The study used DNA fusion gene vaccines encoding patient-specific single chain variable fragment, or idiotype (Id), linked to fragment C (FrC) of...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Immunol Immunother
Main Authors: McCann, Katy J., Godeseth, Rosemary, Chudley, Lindsey, Mander, Ann, Di Genova, Gianfranco, Lloyd-Evans, Paul, Kerr, Jonathan P., Malykh, Vladimir B., Jenner, Matthew W., Orchard, Kim H., Stevenson, Freda K., Ottensmeier, Christian H.
Formato: Artigo
Idioma:Inglês
Publicado: Springer Berlin Heidelberg 2015
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4506484/
https://ncbi.nlm.nih.gov/pubmed/25982371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-015-1703-7
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares